Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist, may alleviate depressive symptoms within hours of administration in treatment resistant depressed patients, and the antidepressant effect may last for several weeks. These unique therapeutic properties have prompted researchers to explore the mechanisms mediating the antidepressant effects of ketamine, but despite many efforts, no consensus on its antidepressant mechanism of action has been reached. Recent preclinical reports have associated the neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) with the antidepressant-like action of ketamine. Here, we review the current evidence for a serotonergic role in ketamine's antidepressant effects. The pharmacological profile of ketamine may include equipotent activity on several non-NMDA targets, and the current hypotheses for the mechanisms responsible for ketamine's antidepressant activity do not appear to preclude the possibility that non-glutamate neurotransmitters are involved in the antidepressant effects. At multiple levels, the serotonergic and glutamatergic systems interact, and such crosstalk could support the notion that changes in serotonergic neurotransmission may impact ketamine's antidepressant potential. In line with these prospects, ketamine may increase 5-HT levels in the prefrontal cortex of rats, plausibly via hippocampal NMDA receptor inhibition and activation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. In addition, a number of preclinical studies suggest that the antidepressant-like effects of ketamine may depend on endogenous activation of 5-HT receptors. Recent imaging and behavioral data predominantly support a role for 5-HT1A or 5-HT1B receptors, but the full range of 5-HT receptors has currently not been systematically investigated in this context. Furthermore, the nature of any 5-HT dependent mechanism in ketamine's antidepressant effect is currently not understood, and therefore, more studies are warranted to confirm this hypothesis and explore the specific pathways that might implicate 5-HT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 7×
“Furthermore, the association between rapamycin (selective mTOR inhibitor), antidepressantlike effects, and ketamine may be ambiguous (Autry et al., 2011; Cleary et al., 2008; Li et al., 2010).”
InfluentialNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“The antidepressant-like effect of ketamine is dependent on rapid synthesis of BDNF mediated by deactivation of eEF2 kinase and decreased phosphorylation of eEF2 (Autry et al., 2011) -”
InfluentialMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 2×
“- Ketamine administration may cause a rapid but transient elevation of extracellular glutamate in the medial prefrontal cortex of rats (Chowdhury et al., 2012; Lorrain et al., 2003; Moghaddam et al., 1997; Sorce et al., 2010) - Ketamine blocks the tonic firing of GABAergic interneurons in rats (Homayoun and Moghaddam,…”
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477 · cited 8×
“However, the relevance of this mechanism for treatment of MDD still remains to be investigated in clinical trials.”
InfluentialHomayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“…al., 2012; Lorrain et al., 2003; Moghaddam et al., 1997; Sorce et al., 2010) - Ketamine blocks the tonic firing of GABAergic interneurons in rats (Homayoun and Moghaddam, 2007) - mTOR activation is essential for ketamine’s antidepressant-like activity and induction of synaptogenesis (Li et al.,…”
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 2×
“, 2011, 2010) - Activation of AMPA receptors is required for the antidepressant-like effects of ketamine (Maeng et al., 2008) - In cell cultures, AMPA receptor activation leads to influx of calcium and release of BDNF (Jourdi et al.”
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Cited by
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz041 · Cited by 92
Tiger, M., Veldman, E. R., Ekman, C.-J., Halldin, C., Svenningsson, P., & Lundberg, J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0844-4 · Cited by 81
Spies, M., James, G. M., Berroterán-Infante, N., Ibeschitz, H., Kranz, G. S., Unterholzner, J., Godbersen, M., Gryglewski, G., Hienert, M., Jungwirth, J., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx085 · Cited by 34
Monoamine involvement in the antidepressant-like effect induced by P2 blockade
Diniz, C. R. A. F., Rodrigues, M., Casarotto, P. C., Pereira, V. S., Crestani, C. C., & Joca, S. R. L. (2017) · Brain Research · doi:10.1016/j.brainres.2017.09.011 · Cited by 25
“Furthermore, the antidepressant-like effect of NOS inhibitors and NMDA antagonists (Diniz et al., 2016) are dependent of serotonin levels in the brain (Harkin et al., 2003; du Jardin et al., 2016; Ulak et al., 2010).”
Zhou, Y., Liu, W., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Zhang, C., & Ning, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.001 · Cited by 23
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
Metadata
- Authors
- du Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 71
- Pages
- 27-38
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2416159552
- Cited by
- 53
- References
- 49
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.